Search Results 381-390 of 17856 for Coagulate

1. Long-term Safety With Vedolizumab Intravenous (IV) in Pediatric Participants With Ulcerative Colitis (UC) or Crohn's Disease (CD) - Mayo Clinic

   ... coagulation, immunological, endocrine/metabolic, neurological, or other medical disorder that, in the opinion of the investigator, would confound the study ...

2. AXIOS™ Gastroenterostomy For Gastric Outlet Obstruction IDE - Mayo Clinic

   Abnormal coagulation INR > 1.5 and not correctable (per the discretion of the physician) or who require continuous complete anticoagulation, and/or any ...

3. A Study to Continue to Evaluate the Safety and Clinical Performance of the MOMENTUM 3 Left Ventricle Assist System

   ... coagulation and heparin induced thrombocytopenia; Participation in any other clinical investigation that is likely to confound study results or affect the ...

4. A Study of Pembrolizumab (MK-3475) Versus Placebo in Combination with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+/HER2-) Breast Cancer - Mayo Clinic

   AST (SGOT) and ALT (SGPT) ≤ 2.5 × ULN. Coagulation. INR or PT ≤ 1.5 × ULN unless participant is receiving anticoagulant therapy as long as PT or aPTT/PTT ...

5. Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer - Mayo Clinic

   Normal coagulation [prothrombin time and partial thromboplastin time within normal limits (±15%)]. Subject has resting baseline oxygen saturation by pulse ...

6. Dendritic Cell Therapy After Cryosurgery in Combination With Pembrolizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Remove by Surgery - Mayo Clinic

   NOTE: Heparin for line patency without detectable lab abnormalities for coagulation will be allowed. Corticosteroid use ≤ 14 days prior to registration ...

7. A Trial to Evaluate the Safety of GEN1046 in Patients with Malignant Solid Tumors - Mayo Clinic

   Have an acceptable coagulation status. Have acceptable renal function. Exclusion Criteria: Ongoing or active infection requiring intravenous treatment with ...

8. Digestive Diseases Physicians - Medical Professionals - Mayo Clinic

   Find gastroenterology, hepatology and digestive disease Physicians at your nearest Mayo Clinic location. Learn about the conditions they treat and ...

9. A Study to Evaluate Estetrol to Treat Moderate-to-Severe Vasomotor Symptoms in Postmenopausal Women - Mayo Clinic

   History of known acquired of congenital coagulopathy or abnormal coagulation factors, including known thrombophilia's; 8. Diabetes mellitus with poor ...

10. Phase 2b Study of Investigational Products in Participants with Interstitial Lung Disease Secondary to Systemic Sclerosis - Mayo Clinic

    Presence of other clinically significant risk of bleeding events, including coagulation or platelet disorders, at the Screening Visit as determined by the ...